References
- Bakalian S, Marshall JC, Logan P et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin. Cancer Res.14(4), 951–956 (2008).
- Streilein JW. Ocular immune privilege and the Faustian dilemma. The Proctor lecture. Invest. Ophthalmol. Vis. Sci.37(10), 1940–1950 (1996).
- Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res.28(5), 329–347 (2009).
- Koevary SB. Ocular immune privilege: a review. Clin. Eye Vis. Care12(3–4), 97–106 (2000).
- de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer65(1), 112–115 (1990).
- Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci.42(7), 1414–1421 (2001).
- Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest. Ophthalmol. Vis. Sci.49(2), 505–510 (2008).
- Jager MJ, Ly LV, El Filali M, Madigan MC. Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes? Prog. Retin. Eye Res.30(2), 129–146 (2011).
- Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol.18(5), 349–355 (2008).
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol.23(11), 549–555 (2002).
- Bronkhorst IH, Ly LV, Jordanova ES et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci.52(2), 643–650 (2011).
- Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int.59(5), 300–305 (2009).
- Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res.167(2), e211–e219 (2011).
- Jensen TO, Schmidt H, Moller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on cancer stage I/II melanoma. J. Clin. Oncol.27(20), 3330–3337 (2009).
- Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest.117(5), 1155–1166 (2007).
- Lin EY, Li JF, Gnatovskiy L et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res.66(23), 11238–11246 (2006).
- Hagemann T, Wilson J, Burke F et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol.176(8), 5023–5032 (2006).
- Hagemann T, Lawrence T, McNeish I et al. ‘Re-educating’ tumor-associated macrophages by targeting NF-κB. J. Exp. Med.205(6), 1261–1268 (2008).
- Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol.22(2), 231–237 (2010).
- Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood104(8), 2224–2234 (2004).